STAT+：FDA警告GLP-1药物存在罕见眼部疾病的潜在风险
摘要
美国食品药品监督管理局（FDA）周一警告称，GLP-1药物存在一种罕见但严重的眼部疾病的潜在风险，并要求制药公司告知患者和医生该风险。该疾病名为非动脉炎性前部缺血性视神经病变（NAION），有时被称为“眼中风”，由视神经血供不足引起。它通常导致突发性视力丧失，严重时可致盲。目前该病尚无经证实的治疗方法。诺和诺德的Ozempic和Wegovy以及礼来的Mounjaro和Zepbound等GLP-1药物因其强效减重效果而广受欢迎，但与任何用于大规模人群的药物一样，在真实世界使用中可能出现临床试验中未发现的副作用。
English
The Food and Drug Administration on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk. The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes referred to as an “eye stroke” and is caused by insufficient blood flow to the optic nerve. It typically causes sudden vision loss and, in severe cases, can lead to blindness. There are currently no proven treatments for the condition. GLP-1 drugs such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound have exploded in popularity for their potent weight loss effects, but as with any drugs that are given to large populations, side effects can show up in real-world use that wer